Selective Cox-2 Inhibitors Industry: Global Market Status and Forecast 2021-2027

Selective Cox-2 Inhibitors Industry: Global Market Status and Forecast 2021-2027

Report Code: KNJ1002724 | No. of Pages: 140 | Category: Pharmaceuticals and Healthcare
Publisher: GRD Survey | Date of Publish: Nov-2021
This report provides a comprehensive analysis of current global Selective Cox-2 Inhibitors market based on segmented types and downstream applications. Major product development trends are discussed  under major downstream segment scenario.This report also focuses on major driving factors and inhibitors that affect the market and competitive landscape. Global and regional leading players in the Selective Cox-2 Inhibitors industry are profiled in a detailed way, with sales data and market share info. This report also includes global and regional market size and forecast, drill-down to top 20 economies.

According to this survey, the global Selective Cox-2 Inhibitors market is estimated to have reached $ xx million in 2020, and projected to grow at a CAGR of xx% to $ xx million by 2027.

Covid-19 pandemic has impacted the supply and demand status for many industries along the supply chain. Global Selective Cox-2 Inhibitors Market Status and Forecast 2021-2027 report makes a brilliant attempt to unveil key opportunities available in the global Selective Cox-2 Inhibitors market under the covid-19 impact to help readers in achieving a better market position. No matter the client is industry insider, potential entrant or investor, the report will provide useful data and information.

The Global Selective Cox-2 Inhibitors Market has been exhibited in detail in the following chapters
Chapter 1 displays the basic product introduction and market overview.
Chapter 2 provides the competition landscape of global Selective Cox-2 Inhibitors industry. 
Chapter 3 provides the market analysis by type and by region
Chapter 4 provides the market analysis by application and by region
Chapter 5-10 presents regional and country market size and forecast, under the context of market drivers and inhibitors analysis. 
Chapter 11 analyses the supply chain, including process chart introduction, upstream key raw material and cost analysis, distributor and downstream buyer analysis.
Chapter 12 provides the market forecast by type and by application
Chapter 13 provides the market forecast by region
Chapter 14 profies global leading players with their revenue, market share, profit margin, major product portfolio and SWOT analysis.
Chapter 15 conclusions

Segmented by Type
    Meloxicam

    Celecoxib

    Etoricoxib

    Imrecoxib

    Etodolac

    Parecoxib

    Other

Segmented by Application
    Rheumatoid Arthritis

    Osteoarthritis

    Spondylosis Chronica Ankylopoietica

    Other

Segmented by Country
    North America
        United States
        Canada
        Mexico
    Europe
        Germany
        France
        UK
        Italy
        Russia
        Spain
    Asia Pacific
        China
        Japan
        Korea
        Southeast Asia
        India
        Australasia
    Central & South America
        Brazil
        Argentina
        Colombia
    Middle East & Africa
        Iran
        Israel
        Turkey
        South Africa
        Saudi Arabia

Key manufacturers included in this survey
    Yung Shin Pharmaceutical

    Teva

    TerSera Therapeutics

    Taro Pharmaceuticals 

    Takeda

    Qilu Pharmaceutical

    PuraCap Pharmaceutical

    Pfizer

    Perrigo

    Novacap

    Mylan

    Merck

    Meda Pharmaceuticals

    Lupin Pharmaceuticals

    Kopran

    Kelun Group

    Iroko Pharmaceuticals

    Hengrui pharmaceutical

    Glenmark Pharmaceuticals

    Geri-Care

    Cipla

    Breckenridge Pharmaceutical

    Boehringer-Ingelheim

    Bayer

    Aurobindo Pharma

    Apotex

    Almirall Limited

    Abbott



Table of Contents

1 Product Introduction and Overview
    1.1 Product Definition
    1.2 Product Specification
    1.3 Global Market Overview
        1.3.1 Global Selective Cox-2 Inhibitors Market Status and Forecast (2016-2027)
        1.3.2 Global Selective Cox-2 Inhibitors Sales Value CAGR by Region
    1.4 Market Drivers, Inhibitors
        1.4.1 Market Drivers
        1.4.2 Market Inhibitors
        1.4.3 COVID-19 Impact Analysis
2 Global Selective Cox-2 Inhibitors Supply by Company
    2.1 Global Selective Cox-2 Inhibitors Sales Value by Company
    2.2 Selective Cox-2 Inhibitors Sales Area of Main Manufacturers
    2.3 Trend of Concentration Rate
3 Global and Regional Selective Cox-2 Inhibitors Market Status by Type
    3.1 Selective Cox-2 Inhibitors Type Introduction
        3.1.1 Meloxicam

        3.1.2 Celecoxib

        3.1.3 Etoricoxib

        3.1.4 Imrecoxib

        3.1.5 Etodolac

        3.1.6 Parecoxib

        3.1.7 Other
    3.2 Global Selective Cox-2 Inhibitors Market by Type
    3.3 North America: by Type
    3.4 Europe: by Type
    3.5 Asia Pacific: by Type
    3.6 Central & South America: by Type
    3.7 Middle East & Africa: by Type
4 Global and Regional Selective Cox-2 Inhibitors Market Status by Application
    4.1 Selective Cox-2 Inhibitors Segment by Application
        4.1.1 Rheumatoid Arthritis

        4.1.2 Osteoarthritis

        4.1.3 Spondylosis Chronica Ankylopoietica

        4.1.4 Other
    4.2 Global Selective Cox-2 Inhibitors Market by Application
    4.3 North America: by Application
    4.4 Europe: by Application
    4.5 Asia Pacific: by Application
    4.6 Central & South America: by Application
    4.7 Middle East & Africa: by Application
5 Global Selective Cox-2 Inhibitors Market Status by Region
    5.1 Global Selective Cox-2 Inhibitors Market by Region
    5.2 North America Selective Cox-2 Inhibitors Market Status
    5.3 Europe Selective Cox-2 Inhibitors Market Status
    5.4 Asia Pacific Selective Cox-2 Inhibitors Market Status
    5.5 Central & South America Selective Cox-2 Inhibitors Market Status
    5.6 Middle East & Africa Selective Cox-2 Inhibitors Market Status
6 North America Selective Cox-2 Inhibitors Market Status
    6.1 North America Selective Cox-2 Inhibitors Market by Country
    6.2 United States
    6.3 Canada
    6.4 Mexico
7 Europe Selective Cox-2 Inhibitors Market Status
    7.1 Europe Selective Cox-2 Inhibitors Market by Country
    7.2 Germany
    7.3 France
    7.4 UK
    7.5 Italy
    7.6 Russia
    7.7 Spain
8 Asia Pacific Selective Cox-2 Inhibitors Market Status
   8.1 Asia Pacific Selective Cox-2 Inhibitors Market by Country
    8.2 China
    8.3 Japan
    8.4 Korea
    8.5 Southeast Asia
    8.6 India
    8.7 Australasia
9 Central & South America Selective Cox-2 Inhibitors Market Status
    9.1 Central & South America Selective Cox-2 Inhibitors Market by Country
    9.2 Brazil
    9.3 Argentina
    9.4 Colombia
10 Middle East & Africa Selective Cox-2 Inhibitors Market Status
    10.1 Middle East & Africa Selective Cox-2 Inhibitors Market by Country
    10.2 Iran
    10.3 Israel
    10.4 Turkey
    10.5 South Africa
    10.8 Saudi Arabia
11 Major Downstream Customers Analysis
    11.1 Customer One Analysis
    11.2 Customer Two Analysis
    11.3 Customer Three Analysis
    11.4 Customer Four Analysis
12 Global Selective Cox-2 Inhibitors Market Forecast by Type and by Application
    12.1 Global Selective Cox-2 Inhibitors Sales Value Forecast (2022-2027)
    12.2 Global Selective Cox-2 Inhibitors Forecast by Type
    12.3 Global Selective Cox-2 Inhibitors Forecast by Application
13 Global Selective Cox-2 Inhibitors Market Forecast by Region/Country
    13.1 Global Selective Cox-2 Inhibitors Market Forecast by Region (2022-2027)
    13.2 North America Market Forecast
    13.3 Europe Market Forecast
    13.4 Asia Pacific Market Forecast
    13.5 Central & South America Market Forecast
    13.6 Middle East & Africa Market Forecast
14 Key Participants Company Information
    14.1 Yung Shin Pharmaceutical

        14.1.1 Company Information
        14.1.2 Selective Cox-2 Inhibitors Product Introduction
        14.1.3 Yung Shin Pharmaceutical
 Selective Cox-2 Inhibitors Sales Value, Gross Margin and Global Share (2019-2021)
        14.1.4 SWOT Analysis
    14.2 Teva

        14.2.1 Company Information
        14.2.2 Selective Cox-2 Inhibitors Product Introduction
        14.2.3 Teva
 Selective Cox-2 Inhibitors Sales Value, Gross Margin and Global Share (2019-2021)
        14.2.4 SWOT Analysis
    14.3 TerSera Therapeutics

        14.3.1 Company Information
        14.3.2 Selective Cox-2 Inhibitors Product Introduction
        14.3.3 TerSera Therapeutics
 Selective Cox-2 Inhibitors Sales Value, Gross Margin and Global Share (2019-2021)
        14.3.4 SWOT Analysis
    14.4 Taro Pharmaceuticals 

        14.4.1 Company Information
        14.4.2 Selective Cox-2 Inhibitors Product Introduction
        14.4.3 Taro Pharmaceuticals 
 Selective Cox-2 Inhibitors Sales Value, Gross Margin and Global Share (2019-2021)
        14.4.4 SWOT Analysis
    14.5 Takeda

        14.5.1 Company Information
        14.5.2 Selective Cox-2 Inhibitors Product Introduction
        14.5.3 Takeda
 Selective Cox-2 Inhibitors Sales Value, Gross Margin and Global Share (2019-2021)
        14.5.4 SWOT Analysis
    14.6 Qilu Pharmaceutical

        14.6.1 Company Information
        14.6.2 Selective Cox-2 Inhibitors Product Introduction
        14.6.3 Qilu Pharmaceutical
 Selective Cox-2 Inhibitors Sales Value, Gross Margin and Global Share (2019-2021)
        14.6.4 SWOT Analysis
    14.7 PuraCap Pharmaceutical

        14.7.1 Company Information
        14.7.2 Selective Cox-2 Inhibitors Product Introduction
        14.7.3 PuraCap Pharmaceutical
 Selective Cox-2 Inhibitors Sales Value, Gross Margin and Global Share (2019-2021)
        14.7.4 SWOT Analysis
    14.8 Pfizer

        14.8.1 Company Information
        14.8.2 Selective Cox-2 Inhibitors Product Introduction
        14.8.3 Pfizer
 Selective Cox-2 Inhibitors Sales Value, Gross Margin and Global Share (2019-2021)
        14.8.4 SWOT Analysis
    14.9 Perrigo

        14.9.1 Company Information
        14.9.2 Selective Cox-2 Inhibitors Product Introduction
        14.9.3 Perrigo
 Selective Cox-2 Inhibitors Sales Value, Gross Margin and Global Share (2019-2021)
        14.9.4 SWOT Analysis
    14.10 Novacap

        14.10.1 Company Information
        14.10.2 Selective Cox-2 Inhibitors Product Introduction
        14.10.3 Novacap
 Selective Cox-2 Inhibitors Sales Value, Gross Margin and Global Share (2019-2021)
        14.10.4 SWOT Analysis
    14.11 Mylan

    14.12 Merck

    14.13 Meda Pharmaceuticals

    14.14 Lupin Pharmaceuticals

    14.15 Kopran

    14.16 Kelun Group

    14.17 Iroko Pharmaceuticals

    14.18 Hengrui pharmaceutical

    14.19 Glenmark Pharmaceuticals

    14.20 Geri-Care

    14.21 Cipla

    14.22 Breckenridge Pharmaceutical

    14.23 Boehringer-Ingelheim

    14.24 Bayer

    14.25 Aurobindo Pharma

    14.26 Apotex

    14.27 Almirall Limited

    14.28 Abbott

15 Conclusion
16 Methodology

NEED Help?

If you need any help or guidance, please feel free to call us.

USA : +1 (661) 636 6162

INDIA : +91 9325802062

or

Write us on : sales@kandjmarketresearch.com